Myovant Sciences Ltd. (MYOV)
NYSE: MYOV
· Real-Time Price · USD
26.98
-0.01 (-0.04%)
At close: Mar 09, 2023, 10:01 PM
Myovant Sciences Revenue Breakdown
| Period Ending | Mar 31, 2022 | Mar 31, 2021 |
|---|---|---|
| Collaboration Agreement Revenue | 121.66M | 55.69M |
| Collaboration Agreement Revenue Growth | +118.48% | n/a |
| Amortization of Regulatory Milestone Revenue | 21.1M | n/a |
| Amortization of Regulatory Milestone Revenue Growth | n/a | n/a |
| Amortization of Upfront Payment Revenue | 83.9M | n/a |
| Amortization of Upfront Payment Revenue Growth | n/a | n/a |
| Revenue Recognized Upon Completion of Delivery Revenue | 16.7M | n/a |
| Revenue Recognized Upon Completion of Delivery Revenue Growth | n/a | n/a |
Revenue by Geography
| Period Ending | Mar 31, 2022 |
|---|---|
| Europe Revenue | 5M |
| Europe Revenue Growth | n/a |
| United States Revenue | 89.31M |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 86.38M | 84.26M | 79.03M | 67.25M | 72.13M | 58.78M | 61.21M | 78.04M | 49.24M | 31.32M | 22.83M | 22.43M | 29.14M | 16.6M | 14.15M | 12.48M | 10.69M | 10.31M | 8.74M | 7.27M | 6.64M | 6.14M | 4.18M | 3.93M | 2.9M | 2.97M | 2.56M |
| Selling, General, and Administrative Revenue Growth | +2.52% | +6.61% | +17.53% | -6.76% | +22.70% | -3.97% | -21.56% | +58.47% | +57.25% | +37.18% | +1.77% | -23.03% | +75.52% | +17.32% | +13.39% | +16.80% | +3.65% | +17.94% | +20.28% | +9.46% | +8.13% | +46.84% | +6.41% | +35.61% | -2.33% | +15.81% | n/a |
| Research and Development Revenue | 31.52M | 26.92M | 23.89M | 24.52M | 25.73M | 26.28M | 30.88M | 21.55M | 30.45M | 40.52M | 44.19M | 41.71M | 48.93M | 50.8M | 51.12M | 59.02M | 58.43M | 53.81M | 51.34M | 40.08M | 34.88M | 24.17M | 17.71M | 19.02M | 6.16M | 3.75M | 14.57M |
| Research and Development Revenue Growth | +17.10% | +12.67% | -2.56% | -4.70% | -2.11% | -14.90% | +43.27% | -29.23% | -24.85% | -8.29% | +5.93% | -14.74% | -3.69% | -0.61% | -13.39% | +1.00% | +8.59% | +4.81% | +28.10% | +14.92% | +44.29% | +36.49% | -6.88% | +208.80% | +64.08% | -74.25% | n/a |